Nutritional products maker USANA's prelim Q3 sales miss estimates

Reuters
2025/10/10
Nutritional products maker USANA's prelim Q3 sales miss estimates

Overview

  • USANA preliminary Q3 net sales of $214 mln missed analyst expectations

  • Preliminary adjusted EPS for Q3 was negative, reflecting sales and productivity challenges

  • Company faced high effective tax rate impacting Q3 profitability

Outlook

  • USANA expects full-year sales at the lower end of previous guidance

  • USANA anticipates future lower tax rate due to cost alignment efforts

Result Drivers

  • COMPENSATION PLAN TRANSITION - Co attributes softer sales and productivity to the rollout of an enhanced Brand Partner compensation plan

  • HIYA SALES - Hiya's lower than anticipated customer acquisition rates led to softer sales in a seasonally strong quarter

  • HIGH TAX RATE - Co faced a significant increase in the effective income tax rate, impacting Q3 profitability

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Prelim Q3 Sales

Miss

$214 mln

$224.10 mln (1 Analyst)

Prelim Q3 EPS

-$0.36

Analyst Coverage

  • Wall Street's median 12-month price target for USANA Health Sciences Inc is $61.00, about 56.5% above its October 8 closing price of $26.51

  • The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw72nDPHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10